Castle Biosciences, Inc.

As of October 24, 2025, Castle Biosciences, Inc. has shifted to a bullish trend, supported by positive indicators like a bullish MACD, Bollinger Bands, and On-Balance Volume, despite mixed signals from the KST and a mildly bullish Dow Theory.

As of October 24, 2025, Castle Biosciences, Inc. shows a bullish trend supported by positive weekly MACD and Bollinger Bands, though caution is advised due to a bearish monthly KST.

As of October 24, 2025, Castle Biosciences, Inc. shows a bullish technical trend with strong indicators, although caution is advised due to a bearish KST signal on the monthly timeframe, while the stock has recently outperformed the S&P 500 in the short term.

As of September 19, 2025, Castle Biosciences, Inc. shows a mildly bullish technical trend overall, supported by bullish weekly MACD and Bollinger Bands, despite mixed signals from monthly indicators and daily moving averages.

As of September 19, 2025, Castle Biosciences, Inc. shows a mildly bullish trend due to positive weekly momentum indicators, despite mixed signals from daily moving averages and longer-term underperformance compared to the S&P 500.

As of September 10, 2025, Castle Biosciences, Inc. shows a mildly bearish trend with mixed technical signals, having returned 14.11% over the past month but underperforming year-to-date at -11.97% compared to the S&P 500's 12.22%.

As of May 5, 2025, Castle Biosciences, Inc. is considered a risky investment due to its overvaluation, reflected in a Price to Book Value of 1.15, an unfavorable EV to EBITDA ratio of 8.54, a negative ROCE of -7.81%, and significant underperformance compared to the S&P 500.

As of May 5, 2025, Castle Biosciences, Inc. is considered overvalued with a valuation grade of risky, highlighted by a P/E ratio of -127.48, a year-to-date return of -29.27%, and key ratios indicating poor financial performance compared to its peers.

As of June 9, 2025, the market trend is mildly bearish, indicated by daily moving averages and weekly Bollinger Bands, despite some mixed signals from MACD and KST suggesting a lack of strong momentum.

Castle Biosciences, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $88 million and a net loss of $26 million as of March 2025. The company has a market cap of $535.29 million and does not pay dividends.

As of Jun 18, Castle Biosciences, Inc. has a market capitalization of 535.29 million, with net sales of 347.08 million and a net profit of -5.07 million over the latest four quarters.